Works matching DE "BISPECIFIC antibodies"
Results: 1199
Combination of cadonilimab (PD-1/CTLA-4 bispecific antibody) and apatinib as salvage therapy achieves partial response in MSI-H advanced gastric cancer: a case report.
- Published in:
- Frontiers in Immunology, 2025, p. 1, doi. 10.3389/fimmu.2025.1533700
- By:
- Publication type:
- Article
Dexamethasone for the management of CRS Related to teclistamab in patients with relapsed/refractory multiple myeloma.
- Published in:
- Blood Cancer Journal, 2025, v. 15, n. 1, p. 1, doi. 10.1038/s41408-025-01222-y
- By:
- Publication type:
- Article
Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis.
- Published in:
- Journal of Hematology & Oncology, 2025, v. 18, n. 1, p. 1, doi. 10.1186/s13045-025-01678-2
- By:
- Publication type:
- Article
Targeting GPRC5D With Talquetamab: A New Frontier in Bispecific Antibody Therapy for Relapsed/Refractory Multiple Myeloma.
- Published in:
- Annals of Pharmacotherapy, 2025, v. 59, n. 4, p. 350, doi. 10.1177/10600280241271192
- By:
- Publication type:
- Article
BCMA-targeted therapies for multiple myeloma: latest updates from 2024 ASH annual meeting.
- Published in:
- Journal of Hematology & Oncology, 2025, v. 18, n. 1, p. 1, doi. 10.1186/s13045-025-01675-5
- By:
- Publication type:
- Article
The Development and Application of Bispecific Antibodies in B-Cell Non-Hodgkin Lymphoma.
- Published in:
- Journal of Personalized Medicine, 2025, v. 15, n. 2, p. 51, doi. 10.3390/jpm15020051
- By:
- Publication type:
- Article
Monoclonal Antibodies in Relapsed-Refractory Multiple Myeloma.
- Published in:
- Pharmaceuticals (14248247), 2025, v. 18, n. 2, p. 145, doi. 10.3390/ph18020145
- By:
- Publication type:
- Article
Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 128, doi. 10.3390/vaccines13020128
- By:
- Publication type:
- Article
Emerging Immunotherapies for Advanced Non-Small-Cell Lung Cancer.
- Published in:
- Vaccines, 2025, v. 13, n. 2, p. 128, doi. 10.3390/vaccines13020128
- By:
- Publication type:
- Article
Advances in Biologic Therapies for Allergic Diseases: Current Trends, Emerging Agents, and Future Perspectives.
- Published in:
- Journal of Clinical Medicine, 2025, v. 14, n. 4, p. 1079, doi. 10.3390/jcm14041079
- By:
- Publication type:
- Article
Optical Coherence Tomography Angiography Flow Signal in Non-Treatment-Naïve Patients with Neovascular Age-Related Macular Degeneration Treated with Faricimab.
- Published in:
- Medicina (1010660X), 2025, v. 61, n. 2, p. 260, doi. 10.3390/medicina61020260
- By:
- Publication type:
- Article
Antibody Therapy for Patients with Lymphoid Malignancies: Past and Present.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1711, doi. 10.3390/ijms26041711
- By:
- Publication type:
- Article
Advances in Antibody-Based Immune-Stimulating Drugs: Driving Innovation in Cancer Therapy.
- Published in:
- International Journal of Molecular Sciences, 2025, v. 26, n. 4, p. 1440, doi. 10.3390/ijms26041440
- By:
- Publication type:
- Article
Bispecific antibody toxicities.
- Published in:
- Canadian Medical Association Journal (CMAJ), 2025, v. 197, n. 7, p. E190, doi. 10.1503/cmaj.241384
- By:
- Publication type:
- Article
Targeting Herpes Simplex Virus Glycoprotein D with Bispecific Antibodies: Expanding Therapeutic Horizons by Searching for Synergy.
- Published in:
- Viruses (1999-4915), 2025, v. 17, n. 2, p. 249, doi. 10.3390/v17020249
- By:
- Publication type:
- Article
Decorated DNA‐Based Scaffolds as Lateral Flow Biosensors.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 47, p. 1, doi. 10.1002/ange.202313243
- By:
- Publication type:
- Article
Trimming Crystallizable Fragment (Fc) Glycans Enables the Direct Enzymatic Transfer of Biomacromolecules to Antibodies as Therapeutics.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 36, p. 1, doi. 10.1002/ange.202308174
- By:
- Publication type:
- Article
Dendronized DNA Chimeras Harness Scavenger Receptors To Degrade Cell Membrane Proteins.
- Published in:
- Angewandte Chemie, 2023, v. 135, n. 13, p. 1, doi. 10.1002/ange.202300694
- By:
- Publication type:
- Article
Chemoenzymatic Synthesis of a Rhamnose‐Functionalized Bispecific Nanobody as a Bispecific Antibody Mimic for Cancer Immunotherapy.
- Published in:
- Angewandte Chemie, 2022, v. 134, n. 38, p. 1, doi. 10.1002/ange.202208773
- By:
- Publication type:
- Article
Genetically Programmable Fusion Cellular Vesicles for Cancer Immunotherapy.
- Published in:
- Angewandte Chemie, 2021, v. 133, n. 50, p. 26524, doi. 10.1002/ange.202108342
- By:
- Publication type:
- Article
Visualization of the frequency effect of pulsed electric field on enzymatic browning of peel ground tissue.
- Published in:
- Food & Bioproducts Processing: Transactions of the Institution of Chemical Engineers Part C, 2023, v. 142, p. 82, doi. 10.1016/j.fbp.2023.09.003
- By:
- Publication type:
- Article
The preparation of VEGFR1/CD3 bispecific antibody and its specific cytotoxicity against VEGFR1-positive breast cancer cells.
- Published in:
- Biotechnology & Applied Biochemistry, 2014, v. 61, n. 4, p. 376, doi. 10.1002/bab.1187
- By:
- Publication type:
- Article
Advancement in the development of single chain antibodies using phage display technology.
- Published in:
- PeerJ, 2024, p. 1, doi. 10.7717/peerj.17143
- By:
- Publication type:
- Article
Engineering a tunable bicistronic TetR autoregulation expression system in Gluconobacter oxydans.
- Published in:
- PeerJ, 2022, p. 1, doi. 10.7717/peerj.13639
- By:
- Publication type:
- Article
Intravitreal faricimab for treatment naïve patients with neovascular age-related macular degeneration: a real-world prospective study.
- Published in:
- International Journal of Retina & Vitreous, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40942-024-00586-w
- By:
- Publication type:
- Article
Review of real-world evidence of dual inhibition of VEGF-A and ANG-2 with faricimab in NAMD and DME.
- Published in:
- International Journal of Retina & Vitreous, 2024, v. 10, n. 1, p. 1, doi. 10.1186/s40942-024-00525-9
- By:
- Publication type:
- Article
VH-CH1 switch region-inserting multispecific antibody designs and their efficacy against SARS-CoV-2 in vitro and in vivo.
- Published in:
- Cell Discovery, 2023, v. 9, n. 1, p. 1, doi. 10.1038/s41421-023-00616-1
- By:
- Publication type:
- Article
A bispecific nanobody dimer broadly neutralizes SARS-CoV-1 & 2 variants of concern and offers substantial protection against Omicron via low-dose intranasal administration.
- Published in:
- Cell Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41421-022-00497-w
- By:
- Publication type:
- Article
Combating the SARS-CoV-2 Omicron (BA.1) and BA.2 with potent bispecific antibodies engineered from non-Omicron neutralizing antibodies.
- Published in:
- Cell Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41421-022-00463-6
- By:
- Publication type:
- Article
Novel sarbecovirus bispecific neutralizing antibodies with exceptional breadth and potency against currently circulating SARS-CoV-2 variants and sarbecoviruses.
- Published in:
- Cell Discovery, 2022, v. 8, n. 1, p. 1, doi. 10.1038/s41421-022-00401-6
- By:
- Publication type:
- Article
Zirconium-89 labeled antibodies: general considerations towards radioisotope production and labelling strategies.
- Published in:
- Macedonian Pharmaceutical Bulletin / Makedonsko Farmacevtski Bilten, 2023, v. 69, p. 151, doi. 10.33320/maced.pharm.bull.2023.69.03.074
- By:
- Publication type:
- Article
Stage specific consumption and utilization of aphids, conspecific and heterospecific eggs by two species of Coccinella (Coleoptera: Coccinellidae).
- Published in:
- European Journal of Entomology, 2014, v. 111, n. 3, p. 363, doi. 10.14411/eje.2014.046
- By:
- Publication type:
- Article
Functional response and predatory interactions in conspecific and heterospecific combinations of two congeneric species (Coleoptera: Coccinellidae).
- Published in:
- European Journal of Entomology, 2014, v. 111, n. 2, p. 257, doi. 10.14411/eje.2014.025
- By:
- Publication type:
- Article
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01200-w
- By:
- Publication type:
- Article
Elranatamab monotherapy in the real-word setting in relapsed-refractory multiple myeloma: results of the French compassionate use program on behalf of the IFM.
- Published in:
- Blood Cancer Journal, 2024, v. 14, p. 1, doi. 10.1038/s41408-024-01200-w
- By:
- Publication type:
- Article
Bispecific antibodies targeting BCMA or GPRC5D are highly effective in relapsed myeloma after CAR T-cell therapy.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01197-2
- By:
- Publication type:
- Article
Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01160-1
- By:
- Publication type:
- Article
Impact of age on treatment utilization for newly diagnosed multiple myeloma: a nationwide retrospective cohort study.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01164-x
- By:
- Publication type:
- Article
Bispecific antibodies in the treatment of multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01139-y
- By:
- Publication type:
- Article
Disparities in relapsed or refractory multiple myeloma: recommendations from an interprofessional consensus panel.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01129-0
- By:
- Publication type:
- Article
A roadmap towards improving outcomes in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01115-6
- By:
- Publication type:
- Article
Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma.
- Published in:
- 2024
- By:
- Publication type:
- Letter
IgG replacement in multiple myeloma.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01107-6
- By:
- Publication type:
- Article
Improving outcomes with anti-BCMA bispecific antibodies with attention to infection.
- Published in:
- 2024
- By:
- Publication type:
- Editorial
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9
- By:
- Publication type:
- Article
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01001-1
- By:
- Publication type:
- Article
Update on the management of relapsed/refractory chronic lymphocytic leukemia.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-01001-1
- By:
- Publication type:
- Article
Bispecific antibodies and CAR-T cells: dueling immunotherapies for large B-cell lymphomas.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00997-w
- By:
- Publication type:
- Article
GPRC5D as a novel target for the treatment of multiple myeloma: a narrative review.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-023-00966-9
- By:
- Publication type:
- Article
Bi- and Tri-specific antibodies in non-Hodgkin lymphoma: current data and perspectives.
- Published in:
- Blood Cancer Journal, 2024, v. 14, n. 1, p. 1, doi. 10.1038/s41408-024-00989-w
- By:
- Publication type:
- Article